Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
05 Februar 2024 - 3:00PM
Yiviva, a clinical-stage, platform biotechnology company developing
systems biology medicines to treat aging-related diseases, signed a
memorandum of understanding (MOU) with AstraZeneca China to
establish a research and development collaboration at AstraZeneca’s
Innovation Campus (iCampus) in Chengdu, China. The signing ceremony
took place at the 2023 China International Import Expo (CIIE) at
the National Exhibition and Convention Center in Shanghai. To
address global unmet medical needs, Together Yiviva and AstraZeneca
China will jointly build platforms for scientific research
transformation and industrial development led by academicians and
experts with the aim to modernize botanical medicines in accordance
with new regulatory pathways for botanical medicines by the United
States Food and Drug Administration (FDA) and China National
Medical Products Administration (NMPA).
“2023 marks the 30th anniversary of AstraZeneca in China. In
collaboration with the Chengdu government and Chengdu High-Tech
Industrial Zone (CDHT), AstraZeneca is establishing a modern
healthcare development platform integrating traditional Chinese
medicine and Western medicine. At CIIE, AstraZeneca announced plans
to further globalize Chinese medicine. Our strategic partnership
with Yiviva, will advance our blueprint for how to develop
innovative medicines inspired by Chinese medicine,” remarked Lily
Zhu, Vice President of AstraZeneca China and Head of DCI and
CSE.
“Disease knows no borders. By bringing together the knowledge
and best practices of Western and Eastern Medicine, WE Medicine, we
can learn from ancient wisdom to develop future medicines. Together
with AstraZeneca China’s expertise, ecosystem, and resources, and
Yiviva’s team, platform technologies, and pipeline, we can pioneer
a new paradigm for systems biology drug development to address
global unmet medical needs,” said Peikwen Cheng, Co-Founder and CEO
of Yiviva.
About Yiviva’s Platforms and Pipeline in
Oncology
Yiviva’s STAR (signal transduction, activity and response) drug
discovery platform accelerates the identification of botanical
therapeutics that influence immune function, inflammatory
responses, cell growth, metabolic functions, and hormone activity.
Through STAR, Yiviva can design sophisticated multi-target drugs
that map to complicated disease biology. Yiviva has discovered six
first-in-class drug candidates to treat cancer and inflammatory
diseases. Yiviva applies patented, mechanism-based quality control
linked to biological activity to manufacture batch-to-batch
consistent drug product that satisfies established regulatory
requirements for complex products.
Yiviva’s lead candidate drug YIV-906 is a proprietary extract of
4 medicinal plants, inspired by an 1800-year-old traditional
Chinese medicine formula. YIV-906 acts as an immunomodulator in the
tumor microenvironment, turning cold tumors hot and potentiating
anti-tumor activity for chemotherapies, immunotherapies, cell
therapies, or radiation therapies; and acts as a cytoprotector in
the gastrointestinal tract, reducing non-hematological toxicities
and speeding up damaged tissue recovery. Yiviva has conducted 8
early-stage clinical trials in solid tumors (hepatocellular
carcinoma, pancreatic cancer, colorectal cancer, and rectal
cancers), with promising data suggesting that YIV-906 could prolong
survival and improve quality of life. Yiviva recently recruited its
last-patient-in in a first-line, randomized, double-blinded Phase
2b study of sorafenib plus YIV-906 in the treatment of
hepatocellular carcinoma patients with hepatitis B. The CALM study
is a multi-regional trial in the United States, Mainland China,
Hong Kong, and Taiwan and expects a data readout in 2024.
Yiviva recently published preclinical data conducted at Yale
University about its novel therapeutic YIV-818-A to treat prostate
cancer. YIV-818-A acts through multiple mechanisms, including
androgen receptor downregulation, glucocorticoid receptor
inhibition, epigenetic regulation and could help overcome drug
resistance to prostate cancer and could enhance apalutamide,
darolutamide, or enzalutamide efficacy.
About Yiviva
Yiviva is a clinical stage, platform biotechnology company
developing systems biology medicines to prevent, treat, and/or cure
aging-related diseases, including cancer and inflammatory diseases.
The company was launched with Yale University and Henry Bronson
Professor of Pharmacology and Medicine Yung-Chi Cheng as
co-founders, with teams in the United States and Greater China.
Yiviva’s investors include the National Foundation for Cancer
Research and the Asian Fund for Cancer Research. For further
information, please visit https://yiviva.com.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on social media @AstraZeneca.
Contact:Email: hello@yiviva.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/8d78fdf0-e819-4a98-abe1-3944978b9ad8
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024